Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI Malaysia ETF (EWM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI Malaysia ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26.02 (market cap $4.49B), while iShares MSCI Malaysia ETF trades at $27.26. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | EWM | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $30.42 |
52-Week Low | $20.06 | $23.49 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EWM, the iShares MSCI Malaysia ETF, trades at $27.24, up 1.0% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The ETF is heavily weighted in Financials (54%) and Industrials (21%), positioning it to benefit from Malaysia's data center expansion and tourism initiatives. A dividend of $0.57 is scheduled for payment on June 18, 2026.
Outlook is mixed: growth potential exists from Malaysia's economic initiatives, but bearish technicals and regional geopolitical risks from Middle East conflicts pose headwinds. Investors should weigh exposure to emerging market volatility against sector-specific opportunities in semiconductors and energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →
